Ȩ Ä«Å×°í¸® ¸ÂÃãÇü½ÃÀåÁ¶»ç ±¹Á¦ÄÁÆÛ·±½º ±Û·Î¹ú ÆÄÆ®³Ê ¸ÞÀϸµ ¼­ºñ½º ȸ»ç¼Ò°³È¸»ç¼Ò°³ Contact Us
English Japaness Chinese
Home > ½ÃÀ庸°í¼­ > ÆÄ¸Ó½´Æ¼Äà > °¨¿°Áúȯ > ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå Àü¸Á(¡­2017³â)
Ä«Å×°í¸®
ÆÄ¸Ó½´Æ¼Äà (4931)
°¨¿°Áúȯ (349)
°ñÁúȯ Ä¡·á (38)
´ç´¢º´ (194)
¹é½Å (181)
ºñ¸¸Ä¡·á/´ÙÀÌ¾îÆ® (44)
ºñó¹æ ÀǾàǰ (152)
¼öÀÇÇÐ (17)
½Å°æÁúȯ (174)
½Å¾à°³¹ß (1529)
¾ÏÄ¡·á (941)
¾à¹°Àü´Þ (185)
ÀǾàǰ ±ÔÁ¦È¯°æ (127)
Á¤½ÅÁúȯ (86)
Á¦³×¸¯ ÀǾàǰ (128)
Á¦¾àȸ»çºÐ¼® (523)
󹿾à (165)
½ÃÀ庸°í¼­

¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå Àü¸Á(¡­2017³â)

Hospital Acquired Bacterial Infections Market to 2017 - Niche Players are Most Active in R&D, Positioning Them as Potential Acquisition Targets for Big Pharma

¸®¼­Ä¡»ç GBI Research
¹ßÇàÀÏ 2011³â 12¿ù »óǰÄÚµå 227586
ÆäÀÌÁö Á¤º¸ Pages: 86
°¡°Ý
US $ 3,500 £Ü 4,170,200 PDF by E-mail (Single user license)
US $ 7,000 £Ü 8,340,500 PDF by E-mail (Site license)
US $ 10,500 £Ü 12,510,700 PDF by E-mail (Global license)


GBI Research ¿¡¼­ 2011³â 12¿ù ¿¡ ¹ßÇàÇÑ ¡¸¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå Àü¸Á(¡­2017³â)¡¹ º¸°í¼­´Â Pages: 86·Î ±¸¼ºµÇ¾î, US $3,500 ºÎÅÍ ±¸¸Å °¡´ÉÇÕ´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿°(HABI) ½ÃÀå¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ÃËÁø¿äÀÎ ¹× ¾ïÁ¦¿äÀÎÀ» ºÐ¼®ÇßÀ¸¸ç, ¹Ì±¹, À¯·´ ÁÖ¿ä 5°³±¹, ÀϺ» ½ÃÀå ºÐ¼®, Ä¡·á ÀÌ¿ë ÆÐÅÏ, ¸ÅÃâ, °¡°Ý, 2017³â±îÁöÀÇ Àü¸Á, ÁÖ¿ä ±â¾÷, M&A µî¿¡ ´ëÇØ Á¤¸®ÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

Á¦1Àå ¸ñÂ÷

Á¦2Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : ¼­·Ð

Á¦3Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : ½ÃÀå °³¿ä

  • ¼­·Ð
  • ¸ÅÃâ Àü¸Á
  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ

Á¦4Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : Ä¡·á »óȲ

  • º´¿ø³» ¿ä·Î°¨¿°Áõ(UTI) ½ÃÀå
  • º´¿ø³» ¼¼±Õ¼ºÆó·Å(HABP) ½ÃÀå
  • º´¿ø³» ¼¼±Õ ¼ö¼úºÎÀ§ °¨¿° ½ÃÀå
  • º´¿ø³» ¼¼±Õ Ç÷¾× °¨¿°(BSI) ½ÃÀå

Á¦5Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : Áö¿ªº° »óȲ

  • Áö¿ªº°
  • ¹Ì±¹
  • À¯·´ ÁÖ¿ä 5°³±¹
  • ÀϺ»

Á¦6Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : ÆÄÀÌÇÁ¶óÀÎ ºÐ¼®

  • °³¹ß ´Ü°èº° ÆÄÀÌÇÁ¶óÀξà
  • ¿¬±¸°³¹ß ÆÄÀÌÇÁ¶óÀÎ
  • ÁÖ¿ä °³¹ß Èıâ´Ü°è ¾àÁ¦ °³¿ä

Á¦7Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : °æÀï ±¸µµ

  • °æÀï ±¸µµ

Á¦8Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : Àü·«Àû ÇÕº´

  • °³¿ä
  • Áö¿ªº° M&A°Å·¡
  • °¡°Ýº° M&A°Å·¡
  • °Å·¡ Á¾·ùº° M&A°Å·¡
  • R&D ¶óÀ̼¾½º °è¾à

Á¦9Àå ¼¼°èÀÇ º´¿ø³» ¼¼±Õ°¨¿° ½ÃÀå : ºÎ·Ï

µµÇ¥

KSA
Back to Top